Cluster Analysis Using Anti–Aminoacyl-tRNA Synthetases and SS-A/Ro52 antibodies in Patients With Polymyositis/Dermatomyositis

Ohashi, Keiji; Sada, Ken Ei; Nakai, Yu; Matsushima, Shun; Asano, Yosuke; Hayashi, Keigo; Yamamura, Yuriko; Hiramatsu, Shinichi; Miyawaki, Yoshia; Morishita, Michiko; Katsuyama, Takayuki; Katsuyama, Eri; Watanabe, Hirotaka; Tatebe, Noriko; Narazaki, Mariko; Matsumoto, Yoshinori; Watanabe, Koichi; Kawabata, Tomoko; Wada, Jun

doi:10.1097/rhu.0000000000000836

Cited by 10 publications

(7 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies that employed cluster analysis exhibited relevant clinical variables in patients with RA, 17,18 systemic sclerosis, 19 and polymyositis/dermatomyositis. 20…”

Section: Introductionmentioning

confidence: 99%

“…Previous studies that employed cluster analysis exhibited relevant clinical variables in patients with RA, 17,18 systemic sclerosis, 19 and polymyositis/dermatomyositis. 20 The purpose of this study was to identify the clinical subgroups of PMR classified under the 2012 EULAR/ACR criteria using cluster analysis and explore clinically relevant variables.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Thrombocytosis as a prognostic factor in polymyalgia rheumatica: characteristics determined from cluster analysis

Hayashi

Ohashi

Watanabe

et al. 2019

Therapeutic Advances in Musculoskeletal

Self Cite

View full text Add to dashboard Cite

Background: This study aimed to identify the clinical subgroups of polymyalgia rheumatica (PMR) using cluster analysis and compare the outcomes among the identified subgroups. Methods: We enrolled patients with PMR who were diagnosed at Okayama University Hospital, Japan between 2006 and 2017, met the 2012 European League Against Rheumatism/American College of Rheumatology provisional classification criteria for PMR, and were treated with glucocorticoids. Hierarchical cluster analysis using variables selected by principal component analysis was performed to identify the clusters. Subsequently, the outcomes among the identified clusters were compared in the study. The primary outcome was treatment response at 1 month after commencement of treatment. The secondary outcome was refractory clinical course, which was defined as the requirement of additional treatments or relapse during a 2-year observational period. Results: A total of 61 consecutive patients with PMR were enrolled in the study. Their mean age was 71 years, and 67% were female. Hierarchical cluster analysis revealed three distinct subgroups: cluster 1 ( n = 14) was characterized by patients with thrombocytosis (all patients showed a platelet count of >45 × 10⁴/µl), cluster 2 ( n = 38), by patients without peripheral arthritis, and cluster 3 ( n = 9), by patients with peripheral arthritis. The patients in cluster 1 achieved treatment response less frequently than those in cluster 2 (14% versus 47%, p = 0.030). Refractory cases were more frequent in cluster 1 than in cluster 2; however, no significant difference was noted (71% versus 42%, p = 0.06). Conclusions: Thrombocytosis could predict the clinical course in patients with PMR.

show abstract

“…Previous studies that employed cluster analysis exhibited relevant clinical variables in patients with RA, 17,18 systemic sclerosis, 19 and polymyositis/dermatomyositis. 20…”

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Thrombocytosis as a prognostic factor in polymyalgia rheumatica: characteristics determined from cluster analysis

Hayashi

Ohashi

Watanabe

et al. 2019

Therapeutic Advances in Musculoskeletal

Self Cite

View full text Add to dashboard Cite

show abstract

“…1,93,94 It was found in 40%-72% of patients with anti-Jo-1 ASSD and up to 70% in those with non-Jo-1 ASSD depending on the population studied, and there was no associated concomitant Sjögren syndrome clinically. 11,[93][94][95][96][97] Some reported that patients with anti-PL7, anti-PL12, and anti-EJ were much more likely to have anti-Ro 52 than those with anti-Jo-1. 32 Presence of anti-Ro 52 in patients with ASSD has been related to more severe ILD, relapses, and refractory disease [97][98][99] ; however, correlation of this autoantibody with degree of myositis, arthritis, or skin manifestations is inconsistent between studies.…”

Section: Anti-ro 52 In Assdmentioning

confidence: 99%

“…11,[93][94][95][96][97] Some reported that patients with anti-PL7, anti-PL12, and anti-EJ were much more likely to have anti-Ro 52 than those with anti-Jo-1. 32 Presence of anti-Ro 52 in patients with ASSD has been related to more severe ILD, relapses, and refractory disease [97][98][99] ; however, correlation of this autoantibody with degree of myositis, arthritis, or skin manifestations is inconsistent between studies. 95,100 Acute onset respiratory failure and development of lung fibrosis was more frequently observed in ASSD with anti-Ro 52 than those without anti-Ro 52, particularly in anti-PL-7 positive patients, 32 with high anti-Ro 52 concentrations showing the highest risk.…”

Section: Anti-ro 52 In Assdmentioning

confidence: 99%

Antisynthetase syndrome: A distinct disease spectrum

Huang

Aggarwal

2020

Journal of Scleroderma and Related Disorders

View full text Add to dashboard Cite

The discovery of novel autoantibodies related to idiopathic inflammatory myopathies (collectively referred to as myositis) has not only advanced our understanding of the clinical, serological, and pathological correlation in the disease spectrum but also played a role in guiding management and prognosis. One group of the myositis-specific autoantibodies is anti-aminoacyl-tRNA synthetase (anti-ARS or anti-synthetase) which defines a syndrome with predominant interstitial lung disease, arthritis, and myositis. Autoantibodies to eight aminoacyl-tRNA synthetases have been identified with anti-Jo1 the most common in all of idiopathic inflammatory myopathies. Disease presentation and prognosis vary depending on which anti-aminoacyl-tRNA synthetase antibody is present. In this review, we will discuss the clinical characteristics, overlap features with other autoimmune diseases, prognostic factors, and management of the antisynthetase syndrome.

show abstract

“…However, the severity of DM is difficult to evaluate as systemic and opportunistic infections in DM patients have become a major influencing factor in DM prognosis, rather than only associated with malignant tumor or ILD [1]. Another study found that six DM cases with isolated anti-Ro-52 in DM rapidly developed progressive ILD, but the patients responded well to therapy and had good prognosis in DM [22]. Our data showed that patients with rapidly progressive ILD expressed antibody MDA5 or antibody MDA5 combined with antibody Ro-52.…”

Section: Patient Characteristicsmentioning

confidence: 99%

The correlation between Ro-52 antibody and interstitial lung disease in dermatomyositis

Xing

Hao

et al. 2020

Preprint

View full text Add to dashboard Cite

Background Recent studies have shown that Ro-52 antibody is associated with interstitial lung disease(ILD) in children with dermatomyositis(DM) and with the degree of disease severity. Moreover, we found that 50% or more cases of adult patients with DM tested positive for antibody Ro-52. Here, we analyzed the correlation between antibody Ro-52 and ILD in inpatients with DM. Objective To explore the correlation between Ro-52 antibody and ILD of DM. Methods A total of 153 patients with DM were collected, who met the classification criteria of idiopathic inflammatory myositis. Immunoblotting was used to detect 16 myositis-specific autoantibodies (MSAs) and myositis-associated autoantibodies (MAAs) from patient serum samples. High-resolution computed tomography (HRCT) was used to calculate the ILD severity score, and the tumors were screened. The clinical data and CT scores were analyzed retrospectively. Results Our data showed that antibodies of Ro-52 and MDA5 were risk factors for ILD development in patients with DM. Antibody Ro-52 was the most commonly occurring (52.9%) antibody in DM patients. The presence of Ro-52 in DM patients strongly suggested the possibility for the occurrence of ILD (86.4%). The severity of Ro-52-positive cases was higher than that of the Ro-52-negative cases.Ro-52 may increase the incidence of ILD when combined with other antibodies of PM-Scl75, PM-Scl100, TIF1-𝛾,Mi-2β,and MDA5. Conclusions The occurrence of ILD is highly likely in patients with DM having the antibody Ro-52. Thus, Ro-52 is a risk factor for ILD in DM.

show abstract

Cluster Analysis Using Anti–Aminoacyl-tRNA Synthetases and SS-A/Ro52 antibodies in Patients With Polymyositis/Dermatomyositis

Abstract: Our cluster analysis shows that anti-SS-A/Ro52 or any anti-ARS antibodies or both might be relevant to clinical outcomes.

Cited by 10 publications

References 32 publications

Thrombocytosis as a prognostic factor in polymyalgia rheumatica: characteristics determined from cluster analysis

Thrombocytosis as a prognostic factor in polymyalgia rheumatica: characteristics determined from cluster analysis

Antisynthetase syndrome: A distinct disease spectrum

The correlation between Ro-52 antibody and interstitial lung disease in dermatomyositis

Contact Info

Product

Resources

About